Diagonal Bio accelerates its commercialisation efforts with the appointment of Anders Wallseth as Senior Commercial Advisor
Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) is pleased to announce the appointment of Anders Wallseth as Senior Commercial Advisor, effective May 5, 2025. Bringing a strong track record from his previous role as Senior Director International Sales at HemoCue, Wallseth’s appointment represents a significant step forward in accelerating the commercial launch and market growth of Diagonal Bio’s LAMPlify® system.
Anders Wallseth brings extensive experience in commercialising medical devices and “point of care” diagnostics in both the veterinary and the human sector, making him a valuable addition to the Diagonal Bio team. He holds an Executive MBA from Copenhagen Business School and has held senior positions in global companies like HemoCue AB and Danaher Corporation as well as start-ups, serving as an employee, board member, partner and consultant.
With an extensive background in the MedTech sector – most recently serving as Senior Director International Sales at HemoCue, a leading Swedish supplier of point-of-care testing solutions for humans and veterinary diagnostics, where he was responsible for all sales outside the US – Wallseth brings a depth of expertise that aligns seamlessly with Diagonal Bio’s strategic priorities as the Company accelerates the commercialisation of its diagnostic platform.
“We are excited to welcome Anders to our team and look forward to leveraging his experience from HemoCue within MedTech. His commercial focus will be key to strengthening the accelerated commercialisation and sales of our LAMPlify® system.” – Karin Wehlin, CEO of Diagonal Bio AB (publ)
“I am excited to contribute to Diagonal Bio’s success by utilizing my experience in commercialisation and sales. With a strong strategic and commercial emphasis, I am confident that the Diagonal Bio LAMPlify® system will become a key player in the market. I look forward to working with Karin and the team to establish Diagonal Bio as a profitable and growing company.” – Anders Wallseth
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio’s patented technology can also be used for the less regulated market segments via LAMPlify®.
